David Linetsky Sells 1,064 Shares of Phreesia (NYSE:PHR) Stock

Key Points

• David Linetsky sold 1,064 shares of Phreesia stock at an average price of $23.50, totaling approximately $25,004, reducing his ownership to 173,888 shares valued at around $4.09 million.
• Phreesia reported a quarterly revenue increase of 14.9% year-over-year, with earnings per share of $0.01, beating the consensus estimate, and it's guided for a loss of $1.1 EPS for the current fiscal year.
• Several research firms upgraded Phreesia's stock rating, with JMP Securities raising the price target from $30.00 to $34.00, while Canaccord Genuity increased theirs from $34.00 to $38.00, indicating a robust outlook for the company.

Phreesia, Inc. (NYSE:PHR - Get Free Report) insider David Linetsky sold 1,064 shares of the business's stock in a transaction on Wednesday, September 17th. The shares were sold at an average price of $23.50, for a total transaction of $25,004.00. Following the sale, the insider owned 173,888 shares of the company's stock, valued at $4,086,368. This trade represents a 0.61% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link.

David Linetsky also recently made the following trade(s):

• On Tuesday, September 16th, David Linetsky sold 2,165 shares of Phreesia stock. The shares were sold at an average price of $23.28, for a total transaction of $50,401.20.
• On Friday, August 22nd, David Linetsky sold 17,445 shares of Phreesia stock. The shares were sold at an average price of $29.73, for a total transaction of $518,639.85.
• On Monday, August 18th, David Linetsky sold 78 shares of Phreesia stock. The stock was sold at an average price of $29.16, for a total transaction of $2,274.48.
• On Thursday, July 17th, David Linetsky sold 2,063 shares of Phreesia stock. The shares were sold at an average price of $26.89, for a total transaction of $55,474.07.
• On Friday, June 27th, David Linetsky sold 23,729 shares of Phreesia stock. The shares were sold at an average price of $28.50, for a total value of $676,276.50.

Phreesia Trading Up 4.3%

Shares of Phreesia stock traded up $1.00 on Thursday, hitting $24.28. The company had a trading volume of 801,987 shares, compared to its average volume of 1,182,744. Phreesia, Inc. has a 1 year low of $17.07 and a 1 year high of $32.76. The company has a debt-to-equity ratio of 0.02, a quick ratio of 2.12 and a current ratio of 2.12. The stock has a 50 day moving average of $27.71 and a 200-day moving average of $26.40.

Phreesia (NYSE:PHR - Get Free Report) last announced its earnings results on Thursday, September 4th. The company reported $0.01 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.07) by $0.08. The company had revenue of $117.26 million for the quarter, compared to analysts' expectations of $116.39 million. Phreesia had a negative return on equity of 8.75% and a negative net margin of 5.35%.Phreesia's quarterly revenue was up 14.9% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.03) earnings per share. Phreesia has set its FY 2026 guidance at EPS. On average, equities analysts forecast that Phreesia, Inc. will post -1.1 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on PHR. JMP Securities raised their price target on shares of Phreesia from $30.00 to $34.00 and gave the company a "market outperform" rating in a research report on Monday, September 8th. Raymond James Financial set a $33.00 price objective on shares of Phreesia and gave the company an "outperform" rating in a research note on Friday, September 5th. DA Davidson upgraded Phreesia to a "strong-buy" rating in a research note on Monday, September 8th. Wall Street Zen raised Phreesia from a "hold" rating to a "buy" rating in a report on Sunday, June 1st. Finally, Canaccord Genuity Group lifted their price target on Phreesia from $34.00 to $38.00 and gave the stock a "buy" rating in a report on Friday, September 5th. One investment analyst has rated the stock with a Strong Buy rating and twelve have issued a Buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Buy" and an average target price of $34.08.

Institutional Investors Weigh In On Phreesia

Several large investors have recently modified their holdings of PHR. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in Phreesia by 108.7% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,644,988 shares of the company's stock valued at $67,606,000 after purchasing an additional 1,377,904 shares during the last quarter. Loomis Sayles & Co. L P purchased a new stake in Phreesia in the second quarter worth $34,162,000. American Century Companies Inc. raised its stake in shares of Phreesia by 3,741.9% in the first quarter. American Century Companies Inc. now owns 983,440 shares of the company's stock valued at $25,137,000 after buying an additional 957,842 shares during the period. Nuveen LLC purchased a new position in shares of Phreesia during the 1st quarter valued at $14,206,000. Finally, Champlain Investment Partners LLC grew its stake in shares of Phreesia by 20.0% during the 1st quarter. Champlain Investment Partners LLC now owns 2,946,489 shares of the company's stock worth $75,312,000 after acquiring an additional 490,340 shares during the period. Hedge funds and other institutional investors own 92.10% of the company's stock.

About Phreesia

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.